NextCure, Inc. (NXTC) Bundle
Understanding NextCure, Inc. (NXTC) Revenue Streams
Understanding NextCure, Inc.’s Revenue Streams
Revenue Sources: Since its inception, the company has not generated any revenue from product sales. Its financial operations are primarily funded through public offerings of common stock and private placements. Additionally, it previously received a $25 million upfront payment from a research and development collaboration agreement.
Year-over-Year Revenue Growth Rate: The company has reported a net loss for the three months ended September 30, 2024, of $11.5 million, compared to a net loss of $14.3 million for the same period in 2023. For the nine months ended September 30, 2024, the net loss was $44.1 million, down from $48.3 million in 2023.
Contribution of Different Business Segments to Overall Revenue: As there are no product sales, the contributions to the overall revenue are solely from the financing activities. The company has raised approximately $423 million in gross proceeds from the sale of equity instruments since inception through September 30, 2024.
Significant Changes in Revenue Streams: There have been no changes to revenue streams as the company continues to focus on research and development without any product revenues. The cash, cash equivalents, and marketable securities as of September 30, 2024, totaled $75.3 million, projected to fund operations into the second half of 2026.
| Period | Net Loss ($ million) | Cash & Equivalents ($ million) | Marketable Securities ($ million) |
|---|---|---|---|
| Q3 2024 | 11.5 | 75.3 | 47.6 |
| Q3 2023 | 14.3 | 19.5 | 12.6 |
| 9M 2024 | 44.1 | 75.3 | 47.6 |
| 9M 2023 | 48.3 | 19.5 | 12.6 |
A Deep Dive into NextCure, Inc. (NXTC) Profitability
A Deep Dive into NextCure, Inc.'s Profitability
Gross Profit Margin: The company reported a gross profit margin of 0% for the nine months ended September 30, 2024, as there were no revenues generated from product sales during this period.
Operating Profit Margin: The operating loss for the nine months ended September 30, 2024, was ($47.3 million), yielding an operating profit margin of 0%.
Net Profit Margin: The net loss for the same period was ($44.1 million), resulting in a net profit margin of 0%.
Trends in Profitability Over Time
The following table outlines the trends in profitability metrics over the past two years:
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Gross Profit Margin | 0% | 0% | 0% |
| Operating Profit Margin | (0%) | (0%) | 0% |
| Net Profit Margin | (0%) | (0%) | 0% |
Comparison of Profitability Ratios with Industry Averages
As of September 30, 2024, NextCure's profitability ratios are significantly lower than the industry averages for biopharmaceutical companies, which typically report:
- Gross Profit Margin: 60%
- Operating Profit Margin: 15%
- Net Profit Margin: 10%
Analysis of Operational Efficiency
The company has incurred substantial losses primarily due to high research and development expenses, which were $32.6 million for the nine months ended September 30, 2024, down from $36.1 million in the previous year.
General and administrative expenses have also decreased to $12.2 million in 2024 from $15.7 million in 2023, indicating some cost management efforts.
The following table summarizes operating expenses:
| Expense Type | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Research and Development | $32.6 million | $36.1 million | ($3.5 million) |
| General and Administrative | $12.2 million | $15.7 million | ($3.5 million) |
| Total Operating Expenses | $47.3 million | $51.8 million | ($4.5 million) |
Despite these reductions, the company continues to face significant operational challenges, as reflected in its persistent net losses.
Debt vs. Equity: How NextCure, Inc. (NXTC) Finances Its Growth
Debt vs. Equity: How NextCure, Inc. Finances Its Growth
As of September 30, 2024, NextCure, Inc. reported total liabilities of $14.753 million. The company has no long-term debt, and its short-term liabilities consist of accounts payable and accrued liabilities. The total stockholders' equity stood at $75.592 million, reflecting a significant reliance on equity financing to support its operations and growth initiatives.
Debt Levels
NextCure has maintained a debt-free status, relying primarily on equity financing to fund its growth. As of the end of September 2024, the company's cash, cash equivalents, and marketable securities totaled $75.3 million, which is projected to support operations through the second half of 2026.
Debt-to-Equity Ratio
The debt-to-equity ratio for NextCure is 0.20, calculated by dividing total liabilities of $14.753 million by total stockholders' equity of $75.592 million. This ratio is significantly lower than the industry average, indicating a conservative approach to leveraging.
Recent Debt Issuances and Credit Ratings
NextCure has not issued any debt instruments recently and maintains a credit rating that reflects its lack of debt obligations. The company continues to focus on raising capital through equity offerings, having raised approximately $423 million from equity instruments since its inception.
Balance Between Debt Financing and Equity Funding
The company has primarily financed its operations through equity, with no reliance on debt financing. In the nine months ended September 30, 2024, net cash provided by financing activities was $0.1 million, mainly from the exercise of stock options and sales of stock under the Employee Stock Purchase Plan (ESPP).
Summary Table of Financial Data
| Financial Metric | Amount |
|---|---|
| Total Liabilities | $14.753 million |
| Total Stockholders' Equity | $75.592 million |
| Cash, Cash Equivalents, Marketable Securities | $75.3 million |
| Debt-to-Equity Ratio | 0.20 |
| Net Cash from Financing Activities (9 months ended September 30, 2024) | $0.1 million |
| Equity Raised Since Inception | $423 million |
Assessing NextCure, Inc. (NXTC) Liquidity
Assessing NextCure, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current assets amounted to $75.3 million, while current liabilities were $14.6 million, resulting in a current ratio of approximately 5.15.
Quick Ratio: With total current assets of $75.3 million and excluding inventory (which is negligible), the quick assets also stand at $75.3 million, producing a quick ratio of approximately 5.15.
Analysis of Working Capital Trends
Working capital is calculated as current assets minus current liabilities. As of September 30, 2024:
Working Capital: $75.3 million (current assets) - $14.6 million (current liabilities) = $60.7 million.
Cash Flow Statements Overview
| Cash Flow Category | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(33,836) | $(42,304) |
| Net Cash Provided by Investing Activities | $48,348 | $35,110 |
| Net Cash Provided by Financing Activities | $108 | $83 |
| Net Increase (Decrease) in Cash and Cash Equivalents | $14,620 | $(7,111) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $75.3 million, which is projected to fund operations into the second half of 2026. However, the company has not generated any revenue to date and anticipates continued operating losses, necessitating additional capital to support ongoing operations and product development.
Future funding may be sought through public and private equity offerings, debt financing, and strategic alliances. If adequate funding is not available, there may be significant delays or reductions in development programs.
Is NextCure, Inc. (NXTC) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the valuation metrics for NextCure, Inc. (NXTC) indicate a challenging financial landscape. The company has not generated revenue from product sales and has accumulated significant losses.
Price-to-Earnings (P/E) Ratio
The company reported a net loss of $44.1 million for the nine months ended September 30, 2024, translating to a basic and diluted loss per share of $1.58. As such, the P/E ratio is not applicable given the absence of earnings.
Price-to-Book (P/B) Ratio
As of September 30, 2024, the total stockholders' equity was $75.6 million, and the book value per share was calculated as follows:
| Total Stockholders' Equity | Shares Outstanding | Book Value per Share |
|---|---|---|
| $75.6 million | 27,975,840 | $2.70 |
The market price of NXTC stock as of September 30, 2024, is needed to compute the P/B ratio, which is currently unavailable.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
NextCure has reported a net loss of $44.1 million for the nine months ended September 30, 2024, with no EBITDA generated due to the lack of revenue. Therefore, the EV/EBITDA ratio is also not applicable.
Stock Price Trends
Over the last 12 months, NextCure's stock price has experienced significant volatility. The stock price as of September 30, 2024, was approximately $6.98, down from a high of around $10.00 within the same period.
Dividend Yield and Payout Ratios
NextCure does not pay dividends, and thus the dividend yield is 0%. The payout ratio is non-applicable as there are no earnings to distribute.
Analyst Consensus on Stock Valuation
As of the latest analysis, the consensus among analysts regarding NextCure's stock is a Hold. This reflects uncertainty surrounding the company’s future revenue generation capabilities and ongoing clinical trials.
| Metric | Value |
|---|---|
| Net Loss (9M 2024) | $44.1 million |
| Basic and Diluted Loss per Share | $1.58 |
| Total Stockholders' Equity | $75.6 million |
| Shares Outstanding | 27,975,840 |
| Book Value per Share | $2.70 |
| Current Stock Price | $6.98 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing NextCure, Inc. (NXTC)
Key Risks Facing NextCure, Inc. (NXTC)
NextCure, Inc. is exposed to a variety of internal and external risks that could significantly impact its financial health and operational viability. Below is a detailed breakdown of these risks.
Industry Competition
The biotechnology sector is characterized by intense competition, particularly in the development of novel therapeutics. As of September 30, 2024, the company has not generated any revenue from product sales, which increases its vulnerability to competitors who may bring products to market more rapidly. The company operates in a space where established players possess greater resources and market presence, potentially limiting its market share and growth opportunities.
Regulatory Changes
Regulatory risk is significant for NextCure as it navigates the complex landscape of clinical trials and product approvals. The company must comply with stringent regulations set forth by the FDA and other regulatory bodies. Any changes in regulatory policies or delays in approvals could lead to increased costs and extended timelines for bringing products to market. For instance, additional clinical trials may be mandated, which could result in substantial financial expenditures and further delays.
Market Conditions
Market conditions, including fluctuations in investor sentiment and capital availability, pose another risk. The company relies on public offerings and private placements to fund its operations. As of September 30, 2024, NextCure had cash, cash equivalents, and marketable securities totaling $75.3 million, which is projected to sustain operations into the second half of 2026. However, unfavorable market conditions could hinder its ability to raise additional funds when needed.
Operational Risks
Operational risks include challenges in managing clinical trials and development programs. The company is currently advancing its lead product candidate, LNCB74, through clinical development. As of the latest reports, research and development expenses for the nine months ended September 30, 2024, amounted to $32.6 million, down from $36.1 million for the same period in 2023. Any setbacks in clinical trials could lead to increased costs and a potential halt in development efforts.
Financial Risks
Financial risks are prevalent, especially given the company's accumulated deficit of $368.5 million as of September 30, 2024. This deficit is primarily the result of ongoing operational losses. For the nine months ended September 30, 2024, the net loss was $44.1 million, slightly improved from $48.3 million in the prior year. The increasing net losses indicate a need for substantial additional funding to support ongoing development activities.
Mitigation Strategies
NextCure has indicated plans to mitigate these risks through various strategies, including:
- Engaging in strategic partnerships to enhance resource allocation and share the financial burden of development costs.
- Maintaining a robust pipeline to diversify its product offerings and reduce dependence on any single candidate.
- Exploring different funding sources, including equity and debt financing to ensure liquidity.
| Risk Factor | Description | Impact on Financial Health |
|---|---|---|
| Industry Competition | Intense competition in biotechnology | Potential loss of market share |
| Regulatory Changes | Compliance with FDA regulations | Increased costs and delays in product approvals |
| Market Conditions | Fluctuations in investor sentiment | Challenges in raising capital |
| Operational Risks | Challenges in managing clinical trials | Increased costs and potential development halts |
| Financial Risks | Accumulated deficit and ongoing losses | Need for substantial additional funding |
Future Growth Prospects for NextCure, Inc. (NXTC)
Future Growth Prospects for NextCure, Inc.
Product Innovations
The company is advancing its lead product candidate, LNCB74, which targets specific cancer pathways. The ongoing Phase 1b/2 clinical trial of NC410 in combination with pembrolizumab is expected to generate significant data that could attract further investment and partnership opportunities.
Market Expansions
NextCure is focusing on expanding its market presence through strategic partnerships. As of September 30, 2024, the company had cash, cash equivalents, and marketable securities of $75.3 million, which it anticipates will fund operations into the second half of 2026.
Acquisitions
The company is exploring potential acquisitions that align with its therapeutic focus, particularly in oncology. The ability to integrate complementary technologies could enhance its product pipeline and market reach.
Future Revenue Growth Projections
Analysts project that NextCure could generate significant revenue following regulatory approvals. However, as of September 30, 2024, the company has not generated any revenue from product sales. The estimated net loss for the nine months ended September 30, 2024, was $44.1 million, a decrease from $48.3 million in the same period in 2023.
Strategic Initiatives and Partnerships
NextCure's collaboration with LigaChem Biosciences is a key strategic initiative that may facilitate access to advanced drug development capabilities and shared resources. The company is also leveraging its employee stock purchase plan to align employee interests with long-term growth.
Competitive Advantages
NextCure possesses a robust intellectual property portfolio and a specialized focus on cancer therapies, providing a competitive edge in the biopharmaceutical landscape. The company has raised approximately $423 million in gross proceeds since its inception, which supports its research and development activities.
| Key Financial Metrics | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) | Change |
|---|---|---|---|
| Net Loss | $44.1 million | $48.3 million | $4.2 million (Decrease) |
| Cash, Cash Equivalents & Marketable Securities | $75.3 million | $xx million | Increase |
| Research & Development Expenses | $32.6 million | $36.1 million | $3.5 million (Decrease) |
| General & Administrative Expenses | $12.2 million | $15.7 million | $3.5 million (Decrease) |
These metrics illustrate the company's financial trajectory and highlight areas where operational efficiencies are being realized.
NextCure, Inc. (NXTC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- NextCure, Inc. (NXTC) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of NextCure, Inc. (NXTC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View NextCure, Inc. (NXTC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.